{"DataElement":{"publicId":"7580684","version":"1","preferredName":"Investigational CAR T-Lymphocyte Agent Type","preferredDefinition":"In the process of being studied; experimental._A cell-surface receptor that has been engineered to combine novel features and specificities from various sources in order to enhance its antigen specificity. Engineered T-cells or B-cells will produce the specialized receptor that will be capable of binding to an epitope on its target cell._A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._Something distinguishable as an identifiable class based on common qualities._Prior action or administration of therapeutic agents that produced an effect that is intended to alter or stop a pathologic process._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)_The words or language units by which a thing is known._Something distinguishable as an identifiable class based on common qualities._A cell-surface receptor that has been engineered to combine novel features and specificities from various sources in order to enhance its antigen specificity. Engineered T-cells or B-cells will produce the specialized receptor that will be capable of binding to an epitope on its target cell.","longName":"INV_CART_PROD_TYP","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"7580676","version":"1","preferredName":"Investigational CAR T-Lymphocyte Agent Type","preferredDefinition":"In the process of being studied; experimental._A cell-surface receptor that has been engineered to combine novel features and specificities from various sources in order to enhance its antigen specificity. Engineered T-cells or B-cells will produce the specialized receptor that will be capable of binding to an epitope on its target cell._A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._Something distinguishable as an identifiable class based on common qualities.","longName":"7580674v1.0:2223243v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"7580674","version":"1","preferredName":"Investigational Chimeric Antigen Receptor T-Lymphocyte Agent","preferredDefinition":"In the process of being studied; experimental.:A cell-surface receptor that has been engineered to combine novel features and specificities from various sources in order to enhance its antigen specificity. Engineered T-cells or B-cells will produce the specialized receptor that will be capable of binding to an epitope on its target cell.:A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","longName":"C28041:C126108:C12476:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Investigational","conceptCode":"C28041","definition":"In the process of being studied; experimental.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Chimeric Antigen Receptor","conceptCode":"C126108","definition":"A cell-surface receptor that has been engineered to combine novel features and specificities from various sources in order to enhance its antigen specificity. Engineered T-cells or B-cells will produce the specialized receptor that will be capable of binding to an epitope on its target cell.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"T-Lymphocyte","conceptCode":"C12476","definition":"A thymocyte-derived lymphocyte of immunological importance that is long-lived (months to years) and is responsible for cell-mediated immunity. T lymphocyte cells form rosettes with sheep erythrocytes and, in the presence of transforming agents (mitogens), differentiate and divide. These cells have the characteristic T3 surface marker and may be further divided into subsets according to function, such as helper, cytotoxic, etc.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB9251E3-82BE-4715-E053-4EBD850A6E25","latestVersionIndicator":"Yes","beginDate":"2021-02-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-17","modifiedBy":"ONEDATA","dateModified":"2021-02-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2223243","version":"1","preferredName":"Type","preferredDefinition":"A subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F629F5E5-DE63-1DFD-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB9251E3-82CC-4715-E053-4EBD850A6E25","latestVersionIndicator":"Yes","beginDate":"2021-02-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-17","modifiedBy":"ARCHERJ","dateModified":"2021-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7580678","version":"1","preferredName":"Chimeric Antigen Receptor Agent Type","preferredDefinition":"Prior action or administration of therapeutic agents that produced an effect that is intended to alter or stop a pathologic process._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)_The words or language units by which a thing is known._Something distinguishable as an identifiable class based on common qualities._A cell-surface receptor that has been engineered to combine novel features and specificities from various sources in order to enhance its antigen specificity. Engineered T-cells or B-cells will produce the specialized receptor that will be capable of binding to an epitope on its target cell.","longName":"CAR_AGT_TYP","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559666","version":"1","preferredName":"Other","longName":"2559666","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B61F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"LISU","dateModified":"2023-08-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BB92C247-6B63-07C0-E053-4EBD850A512C","beginDate":"2021-02-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-17","modifiedBy":"ONEDATA","dateModified":"2021-02-17","deletedIndicator":"No"},{"value":"Seattle","valueDescription":"Seattle","ValueMeaning":{"publicId":"7580679","version":"1","preferredName":"Seattle","longName":"7580679","preferredDefinition":"CAR T-cell investigational product Seattle","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB92C247-6B6D-07C0-E053-4EBD850A512C","latestVersionIndicator":"Yes","beginDate":"2021-02-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-17","modifiedBy":"ONEDATA","dateModified":"2021-02-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BB92C247-6B86-07C0-E053-4EBD850A512C","beginDate":"2021-02-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-17","modifiedBy":"ONEDATA","dateModified":"2021-02-17","deletedIndicator":"No"},{"value":"UCAR","valueDescription":"UCAR","ValueMeaning":{"publicId":"7580680","version":"1","preferredName":"UCAR","longName":"7580680","preferredDefinition":"CAR T-cell investigational product UCAR","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB92C247-6B90-07C0-E053-4EBD850A512C","latestVersionIndicator":"Yes","beginDate":"2021-02-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-17","modifiedBy":"ONEDATA","dateModified":"2021-02-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BB92C247-6BA9-07C0-E053-4EBD850A512C","beginDate":"2021-02-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-17","modifiedBy":"ONEDATA","dateModified":"2021-02-17","deletedIndicator":"No"},{"value":"CHOP","valueDescription":"CHOP_CAR_product","ValueMeaning":{"publicId":"7580681","version":"1","preferredName":"CHOP_CAR_product","longName":"7580681","preferredDefinition":"CAR T-cell investigational product CHOP","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB92C247-6BB3-07C0-E053-4EBD850A512C","latestVersionIndicator":"Yes","beginDate":"2021-02-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-17","modifiedBy":"ONEDATA","dateModified":"2021-02-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BB92C247-6BCC-07C0-E053-4EBD850A512C","beginDate":"2021-02-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-17","modifiedBy":"ONEDATA","dateModified":"2021-02-17","deletedIndicator":"No"},{"value":"NCI","valueDescription":"National Cancer Institute","ValueMeaning":{"publicId":"2569729","version":"1","preferredName":"National Cancer Institute","longName":"2569729","preferredDefinition":"NCI.  The National Cancer Institute, part of the National Institutes of Health of the United States Department of Health and Human Services, is the Federal Government's principal agency for cancer research.  NCI conducts, coordinates, and funds cancer research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer.  Access the NCI Web site at http://cancer.gov.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"National Cancer Institute","conceptCode":"C19202","definition":"The Federal Government's principal agency for cancer research. NCI conducts, coordinates, and funds cancer research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer. Part of the National Institutes of Health of the United States Department of Health and Human Services.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-DD6E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-06-02","modifiedBy":"REEVESD","dateModified":"2006-02-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BB92C247-6BD6-07C0-E053-4EBD850A512C","beginDate":"2021-02-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-17","modifiedBy":"ONEDATA","dateModified":"2021-02-17","deletedIndicator":"No"},{"value":"JCAR","valueDescription":"JCAR","ValueMeaning":{"publicId":"7580682","version":"1","preferredName":"JCAR","longName":"7580682","preferredDefinition":"CAR T-cell investigational product JCAR","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB92C247-6BE0-07C0-E053-4EBD850A512C","latestVersionIndicator":"Yes","beginDate":"2021-02-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-17","modifiedBy":"ONEDATA","dateModified":"2021-02-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BB92C247-6BF9-07C0-E053-4EBD850A512C","beginDate":"2021-02-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-17","modifiedBy":"ONEDATA","dateModified":"2021-02-17","deletedIndicator":"No"},{"value":"KITE","valueDescription":"KITE","ValueMeaning":{"publicId":"7580683","version":"1","preferredName":"KITE","longName":"7580683","preferredDefinition":"CAR T-cell investigational product KITE","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB92C247-6C03-07C0-E053-4EBD850A512C","latestVersionIndicator":"Yes","beginDate":"2021-02-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-17","modifiedBy":"ONEDATA","dateModified":"2021-02-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BB92C247-6C1C-07C0-E053-4EBD850A512C","beginDate":"2021-02-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-17","modifiedBy":"ONEDATA","dateModified":"2021-02-17","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7580677","version":"1","preferredName":"Agent Chimeric Antigen Receptor Type","preferredDefinition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.:A cell-surface receptor that has been engineered to combine novel features and specificities from various sources in order to enhance its antigen specificity. Engineered T-cells or B-cells will produce the specialized receptor that will be capable of binding to an epitope on its target cell.:Something distinguishable as an identifiable class based on common qualities.","longName":"C1708:C126108:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Chimeric Antigen Receptor","conceptCode":"C126108","definition":"A cell-surface receptor that has been engineered to combine novel features and specificities from various sources in order to enhance its antigen specificity. Engineered T-cells or B-cells will produce the specialized receptor that will be capable of binding to an epitope on its target cell.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB92C247-6B3F-07C0-E053-4EBD850A512C","latestVersionIndicator":"Yes","beginDate":"2021-02-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-17","modifiedBy":"ONEDATA","dateModified":"2021-02-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB92C247-6B50-07C0-E053-4EBD850A512C","latestVersionIndicator":"Yes","beginDate":"2021-02-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-17","modifiedBy":"ARCHERJ","dateModified":"2021-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Type of Investigational Produ","type":"Preferred Question Text","description":"Type of Investigational Product:","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB92C247-6C28-07C0-E053-4EBD850A512C","latestVersionIndicator":"Yes","beginDate":"2021-02-17","endDate":null,"createdBy":"ARCHERJ","dateCreated":"2021-02-17","modifiedBy":"MAESKEB","dateModified":"2021-10-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}